Kevin became Chief Medical Officer in 2025, previously serving as Senior Vice President and Vice President of Clinical Development since joining atai in 2021. He is responsible for developing and driving the execution of clinical development, regulatory affairs, drug safety, biostatistics and global clinical operations.

Kevin has over 20 years of clinical experience and has spent the past decade leading global medical teams, and clinical development in neuroscience pipelines. Before joining the industry, Kevin held a faculty appointment at the Behavioral and Clinical Neuroscience Institute at the University of Cambridge and has published widely on the cognition and brain imaging in mental health. He began his industry career at P1vital, developing imaging and cognitive biomarkers to enhance decision-making for early-phase psychiatry trials.

He received his medical degree from the University of Witwatersrand, South Africa, and holds a MPhil in Medical Science from the University of Cambridge. He is a member of the Royal College of Psychiatrists and holds specialist accreditation in addiction and adult psychiatry.